Cargando…

Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?

Successful discontinuation of cabergoline (CAB) treatment has been reported in 31–75% of prolactinomas patients treated for at least 2 years. In contrast, it is not well established whether CAB therapy can be successfully withdrawn after a failed first attempt. This prospective open trial was design...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilar, Lucio, Albuquerque, José Luciano, Gadelha, Patrícia Sampaio, Rangel Filho, Frederico, Siqueira, Aline Maria C., da Fonseca, Maíra Melo, Viana, Karoline Frazão, Gomes, Barbara Sales, Lyra, Ruy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316769/
https://www.ncbi.nlm.nih.gov/pubmed/25699020
http://dx.doi.org/10.3389/fendo.2015.00011
_version_ 1782355614609965056
author Vilar, Lucio
Albuquerque, José Luciano
Gadelha, Patrícia Sampaio
Rangel Filho, Frederico
Siqueira, Aline Maria C.
da Fonseca, Maíra Melo
Viana, Karoline Frazão
Gomes, Barbara Sales
Lyra, Ruy
author_facet Vilar, Lucio
Albuquerque, José Luciano
Gadelha, Patrícia Sampaio
Rangel Filho, Frederico
Siqueira, Aline Maria C.
da Fonseca, Maíra Melo
Viana, Karoline Frazão
Gomes, Barbara Sales
Lyra, Ruy
author_sort Vilar, Lucio
collection PubMed
description Successful discontinuation of cabergoline (CAB) treatment has been reported in 31–75% of prolactinomas patients treated for at least 2 years. In contrast, it is not well established whether CAB therapy can be successfully withdrawn after a failed first attempt. This prospective open trial was designed to address this topic and to try to identify possible predictor factors. Among 180 patients with prolactinomas on CAB therapy, the authors selected those who fulfilled very strict criteria, particularly additional CAB therapy for at least 2 years, normalization of serum prolactin (PRL) levels following CAB restart, no tumor remnant >10 mm, no previous pituitary radiotherapy or surgery; and current CAB dose ≤1.0 mg/week. Recurrence was defined as an increase of PRL levels above the upper limit of normal. A total of 34 patients (70.6% female) treated with CAB for 24–30 months were recruited. Ten patients (29.4%) remained without evidence of recurrence after 24–26 months of follow-up. Twenty-four patients (70.6%) recurred within 15 months (75% within 12 months) after drug withdrawal and ~80% were restarted CAB. Median time to recurrence was 10.5 months (range, 3–15). Despite overlapping values, non-recurring patients had significantly lower mean PRL levels before withdrawal. Moreover, the recurrence rate was lower in subjects without visible tumor on pituitary magnetic resonance imaging (MRI) than in those with small remnant tumor (60 vs. 79%), though the difference was not statistically significant (P = 0.20). No other characteristic could be identified as a predictor of successful CAB discontinuation. In conclusion, a second attempt of CAB withdrawal after two additional years of therapy may be successful, particularly in patients with lower PRL levels and no visible tumor on pituitary MRI. Close monitoring of PRL level is mandatory, especially within the first year after withdrawal, where most recurrences are detected.
format Online
Article
Text
id pubmed-4316769
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-43167692015-02-19 Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile? Vilar, Lucio Albuquerque, José Luciano Gadelha, Patrícia Sampaio Rangel Filho, Frederico Siqueira, Aline Maria C. da Fonseca, Maíra Melo Viana, Karoline Frazão Gomes, Barbara Sales Lyra, Ruy Front Endocrinol (Lausanne) Endocrinology Successful discontinuation of cabergoline (CAB) treatment has been reported in 31–75% of prolactinomas patients treated for at least 2 years. In contrast, it is not well established whether CAB therapy can be successfully withdrawn after a failed first attempt. This prospective open trial was designed to address this topic and to try to identify possible predictor factors. Among 180 patients with prolactinomas on CAB therapy, the authors selected those who fulfilled very strict criteria, particularly additional CAB therapy for at least 2 years, normalization of serum prolactin (PRL) levels following CAB restart, no tumor remnant >10 mm, no previous pituitary radiotherapy or surgery; and current CAB dose ≤1.0 mg/week. Recurrence was defined as an increase of PRL levels above the upper limit of normal. A total of 34 patients (70.6% female) treated with CAB for 24–30 months were recruited. Ten patients (29.4%) remained without evidence of recurrence after 24–26 months of follow-up. Twenty-four patients (70.6%) recurred within 15 months (75% within 12 months) after drug withdrawal and ~80% were restarted CAB. Median time to recurrence was 10.5 months (range, 3–15). Despite overlapping values, non-recurring patients had significantly lower mean PRL levels before withdrawal. Moreover, the recurrence rate was lower in subjects without visible tumor on pituitary magnetic resonance imaging (MRI) than in those with small remnant tumor (60 vs. 79%), though the difference was not statistically significant (P = 0.20). No other characteristic could be identified as a predictor of successful CAB discontinuation. In conclusion, a second attempt of CAB withdrawal after two additional years of therapy may be successful, particularly in patients with lower PRL levels and no visible tumor on pituitary MRI. Close monitoring of PRL level is mandatory, especially within the first year after withdrawal, where most recurrences are detected. Frontiers Media S.A. 2015-02-04 /pmc/articles/PMC4316769/ /pubmed/25699020 http://dx.doi.org/10.3389/fendo.2015.00011 Text en Copyright © 2015 Vilar, Albuquerque, Gadelha, Rangel Filho, Siqueira, da Fonseca, Viana, Gomes and Lyra. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Vilar, Lucio
Albuquerque, José Luciano
Gadelha, Patrícia Sampaio
Rangel Filho, Frederico
Siqueira, Aline Maria C.
da Fonseca, Maíra Melo
Viana, Karoline Frazão
Gomes, Barbara Sales
Lyra, Ruy
Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?
title Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?
title_full Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?
title_fullStr Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?
title_full_unstemmed Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?
title_short Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?
title_sort second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile?
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316769/
https://www.ncbi.nlm.nih.gov/pubmed/25699020
http://dx.doi.org/10.3389/fendo.2015.00011
work_keys_str_mv AT vilarlucio secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile
AT albuquerquejoseluciano secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile
AT gadelhapatriciasampaio secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile
AT rangelfilhofrederico secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile
AT siqueiraalinemariac secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile
AT dafonsecamairamelo secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile
AT vianakarolinefrazao secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile
AT gomesbarbarasales secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile
AT lyraruy secondattemptofcabergolinewithdrawalinpatientswithprolactinomasafterafailedfirstattemptisitworthwhile